Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer

Completed · Phase 2

Conditions studied: Carcinoma, Renal Cell, Urogenital Neoplasms, Urologic Neoplasms, Kidney Neoplasms

In brief

The purpose of this study is to find out if renal cell (kidney) cancer that has spread to other parts of the body will respond to treatment with motexafin gadolinium (MGd).

Key facts

Study ID

NCT00134186

Run by

Pharmacyclics LLC.

People needed

43

Last updated by the study team

2007-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥ 18 years old
• Histologically confirmed renal cell carcinoma with clinically or pathologically confirmed progression
• Ineligible for interleukin-2 (IL-2) treatment and/or have had 2 or fewer prior treatments
• Measurable disease
• Hemoglobin ≥ 9 mg/dL
• ECOG performance status of 0, 1, or 2
• Willing and able to provide written informed consent

You may not qualify if…

• Inadequate bone marrow, renal and liver function by laboratory criteria
• Absolute neutrophil count < 1500/µL;
• Platelet count < 100,000/µL;
• AST or ALT > 2 x upper limit of normal (ULN);
• Alkaline phosphatase > 5 x ULN;
• Total bilirubin > 2 x ULN;
• Creatinine > 2.0 mg/dL.
• Evidence of central nervous system metastases within past year
• Uncontrolled hypertension
• Known history of porphyria, G6PD deficiency or HIV

Where it is running

• Methodist Hospital — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.